Clinical and regulatory failure
Product development companies depend on trial success, approvals, and commercialization pathways that may not materialize.
- Scope
- Early and mid-stage biotech and pharma holdings
- Materiality
- high
Flerie
Flerie is a Stockholm-based life science investment company that owns and develops a portfolio of biotech, pharmaceutical, and related healthcare businesses. Its portfolio is organized around companies in product development and companies in commercial growth, with investments across Europe, Israel, and the United States.
9
100.41
76.92
| % | |
|---|---|
| Product Development Investments | 78% Early and mid-stage biotech, pharma, and product companies advancing toward clinical proof-of-concept and approvals. |
| Commercial Growth Investments | 22% Companies already selling products or services and scaling market share in life science markets. |
Flerie’s direct counterparties are the founders, management teams, and boards of its portfolio companies rather than...
- Portfolio company management teamsprimary
They receive capital, governance support, and strategic input to advance development and commercialization.
- Founders and co-investorsprimary
They partner with Flerie in financing rounds and value-creation initiatives across the portfolio.
- Patients and healthcare providerssecondary
They are the end beneficiaries of the drugs, diagnostics, and life science solutions developed by portfolio companies.
- Life science service and technology customerssecondary
They buy enabling technologies, tools, or specialized services from commercial growth holdings.
- Public shareholdersprimary
They buy Flerie shares to gain diversified, listed exposure to private life science investing.
Flerie is based in Stockholm and manages a portfolio with exposure to several European markets, Israel, and the United...
- •Headquartered in Stockholm, Sweden
- •Portfolio exposure across several European markets
- •Investment presence in Israel and the United States
- •Cross-border life science investing increases regulatory and valuation complexity
- •Geographic diversification reduces dependence on any single market
Flerie’s strategy is active ownership: it takes board representation, works closely with management, and supports key...
01
Active ownership and board involvementshort-term
Direct governance and operational input help portfolio companies progress faster and with clearer strategic direction.
02
Build value across the development cyclemedium-term
Supporting companies from early research through commercialization increases the chance of capturing long-term value creation.
03
Diversify the life science portfoliomedium-term
A broad mandate across modalities and stages helps balance scientific risk and commercial risk.
Flerie’s main risks come from the valuation and financing characteristics of private life science investing, where...
Valuation risk on private portfolio companies
Many holdings are unlisted and valued using judgment-based methods, so changes in assumptions can materially affect reported value.
- Scope
- Product Development and Commercial Growth portfolios
- Materiality
- high
Liquidity and financing risk
Portfolio companies may require follow-on capital, while Flerie must manage its own funding and investment commitments.
- Scope
- Investment commitments and portfolio support
- Materiality
- high
Foreign exchange risk
Investments span multiple currencies and jurisdictions, creating translation and transaction exposure.
- Scope
- Europe, Israel, United States
- Materiality
- medium
Credit risk on receivables and loan exposures
The company has financial assets such as loan receivables from portfolio companies that may require impairment assessment.
- Scope
- Portfolio financing and other financial assets
- Materiality
- medium
Fair value measurement of portfolio investments
Net asset value and fair value gains/losses
Level 3 valuation methodology
Reported investment carrying values
Expected credit losses on receivables
Profit and carrying value of financial assets
IFRS 16
Lease accounting under IFRS 16
EBITDA, depreciation, and leverage presentation
Tax treatment of holdings
Current tax and deferred tax
: 11/08/2026